|
|
https://mb.cision.com/Public/18595/3759242/92a2223c9ca35e5c_800x800ar.png
UCB Receives Positive CHMP Opinions for Bimekizumab for the Treatment of=
Adults with Psoriatic Arthritis and Axial Spondyloarthritis in the Europea=
n Union
=C2=B7 Positive CHMP opinions are supported by data from four Phase 3 studi=
es that evaluated bimekizumab in active psoriatic arthritis BE COMPLETE... Lire le communiqué |
|
| |
|
| |
|
|
https://mb.cision.com/Public/18595/3749839/a4ab6ae8fd123ec3_800x800ar.png
UCB=E2=80=99s Rozanolixizumab and Zilucoplan Phase 3 Generalized Myasthe=
nia Gravis studies published in prestigious The Lancet Neurology Journal
=C2=B7 MycarinG study publication reports the clinically meaningful and sta=
tistically significant effects of rozanolixizumab across key endpoints in a=
dult... Lire le communiqué |
|
| |
|
| |
|
|
https://mb.cision.com/Public/18595/logo/86a99b25f755738d_org.jpg
Acquisition of own shares
Brussels Belgium, 24 March 2023 =E2=80=93 20:00 CET =E2=80=93 Regulated=
information
Acquisition of own shares
In accordance with article 8:4 of the Royal Decree of 29 April 2019 executi=
ng the Belgian Code on Companies and Associations, UCB=C2=A0SA/NV =E2=80=
=9CUCB=E2=80=9D or the... Lire le communiqué |
|
| |
|
| |
|
|
https://mb.cision.com/Public/18595/3736590/8d6268ff035477cd_800x800ar.png
Bimekizumab Phase 3 Data in Hidradenitis Suppurativa Show Clinically Mea=
ningful, Deep and Maintained Response over 48 Weeks
=C2=B7 Patients treated with investigational bimekizumab, an IL17A and IL=
17F inhibitor, achieved statistically significant and clinically meaningful=
improvements over placebo in signs... Lire le communiqué |
|
| |
|
| |
|
|
https://mb.cision.com/Public/18595/3736472/8b0007373e7b6fa5_800x800ar.png
Acquisition of own shares
Brussels Belgium, 17 March 2023 =E2=80=93 20:00 CET =E2=80=93 Regulated=
information=C2=A0
Acquisition of own shares
In accordance with article 8:4 of the Royal Decree of 29 April 2019 executi=
ng the Belgian Code on Companies and Associations, UCB SA/NV =E2=80=9CUCB=
=E2=80=9D... Lire le communiqué |
|
| |
|
| |
|
|
https://mb.cision.com/Public/18595/3734935/bf96ead5e05d8084_800x800ar.png
UCB to Present Eight Bimekizumab Abstracts at AAD 2023 with Results from=
Studies in Psoriasis, Psoriatic Arthritis and Hidradenitis Suppurativa
=C2=B7 Phase 3 data on investigational bimekizumab in the treatment of adul=
ts with moderate to severe hidradenitis suppurativa to be presented as a la=
tebreaking... Lire le communiqué |
|
| |
|
| |
|
|
https://mb.cision.com/Public/18595/3734959/891f67ad9adaaf50_800x800ar.png
Aitia and UCB Announce Strategic Drug Discovery Collaboration in Hunting=
tons Disease
Brussels, Belgium, and Somerville, MA, March 15th, 2023 18:30 CET: UCB, a=
global biopharmaceutical company, and Aitia, a leader in the application o=
f Causal AI and =E2=80=9CDigital Twins=E2=80=9D to discover and develop... Lire le communiqué |
|
| |
|
| |
